Jothi D, Kulka Linda Anna Michelle
Department of Biochemistry II, Friedrich Schiller University, Jena, Germany.
Institute for Physiological Chemistry, Martin Luther University Halle-Wittenberg, Halle, Germany.
NPJ Aging. 2024 Jul 10;10(1):32. doi: 10.1038/s41514-024-00161-5.
The ability to reprogram patient-derived-somatic cells to IPSCs (Induced Pluripotent Stem Cells) has led to a better understanding of aging and age-related diseases like Parkinson's, and Alzheimer's. The established patient-derived disease models mimic disease pathology and can be used to design drugs for aging and age-related diseases. However, the age and genetic mutations of the donor cells, the employed reprogramming, and the differentiation protocol might often pose challenges in establishing an appropriate disease model. In this review, we will focus on the various strategies for the successful reprogramming and differentiation of patient-derived cells to disease models for aging and age-related diseases, emphasizing the accuracy in the recapitulation of disease pathology and ways to overcome the limitations of its potential application in cell replacement therapy and drug development.
将患者来源的体细胞重编程为诱导多能干细胞（IPSCs）的能力，使人们对衰老以及帕金森病和阿尔茨海默病等与年龄相关的疾病有了更好的理解。已建立的患者来源疾病模型模拟疾病病理学，可用于设计针对衰老和与年龄相关疾病的药物。然而，供体细胞的年龄和基因突变、所采用的重编程方法以及分化方案，在建立合适的疾病模型时往往会带来挑战。在本综述中，我们将重点关注将患者来源的细胞成功重编程和分化为衰老及与年龄相关疾病模型的各种策略，强调在重现疾病病理学方面的准确性以及克服其在细胞替代疗法和药物开发中潜在应用局限性的方法。
